Wells Fargo says Boston Scientific’s CHAMPION-AF trial met all endpoints for WATCHMAN FLX but calls results “good, not great” due to slightly higher stroke rate vs blood thinners.
Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.
Analysts say PALI-2108 offers better safety and efficacy for ulcerative colitis compared to older PDE4 inhibitors.
BofA starts coverage on Bicara Therapeutics with a Buy rating and $35 price target. Ficerafusp alfa shows strong potential in head and neck cancer with clear differentiation over standard care.
